These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6205386)

  • 1. [Clinical pharmacology of 5-azacytidine].
    Robak T
    Pol Tyg Lek; 1984 Feb; 39(7):215-8. PubMed ID: 6205386
    [No Abstract]   [Full Text] [Related]  

  • 2. [Possibilities for the clinical use of 5-azacytidine].
    Veselý J; Cihák A
    Vopr Onkol; 1977; 23(10):65-73. PubMed ID: 74127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine.
    Gaynon PS; Baum ES
    Oncology; 1983; 40(3):192-4. PubMed ID: 6189042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute leukemia with 5-azacytidine (NSC-102816).
    McCredie KB; Bodey GP; Burgess MA; Gutterman JU; Rodriguez V; Sullivan MP; Freireich EJ
    Cancer Chemother Rep; 1973; 57(3):319-23. PubMed ID: 4127393
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-Azacytidine: a new active agent for the treatment of acute leukemia.
    Karon M; Sieger L; Leimbrock S; Finklestein JZ; Nesbit ME; Swaney JJ
    Blood; 1973 Sep; 42(3):359-65. PubMed ID: 4125239
    [No Abstract]   [Full Text] [Related]  

  • 6. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
    Von Hoff DD; Slavik M; Muggia FM
    Ann Intern Med; 1976 Aug; 85(2):237-45. PubMed ID: 60073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-azacytidine--a new anticancer drug with significant activity in acute myeloblastic leukemia.
    von Hoff DD; Slavik M
    Adv Pharmacol Chemother; 1977; 14():285-326. PubMed ID: 70163
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-azacytidine.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1981 May; 26():37-46. PubMed ID: 6168559
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mechanism of cystostatic effect of 5-azacytidine and its usefulness in clinic].
    Veselý J; Cihák A
    Cas Lek Cesk; 1975 May; 114(20):607-11. PubMed ID: 48423
    [No Abstract]   [Full Text] [Related]  

  • 10. 5-Azacytidine/5-Azacitidine.
    Müller AM; Florek M
    Recent Results Cancer Res; 2014; 201():299-324. PubMed ID: 24756801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinblastine, 5-azacytidine, and VP-16-213 therapy for previously treated patients with acute nonlymphocytic leukemia.
    Van Echo DA; Lichtenfeld KM; Wiernik PH
    Cancer Treat Rep; 1977 Nov; 61(8):1599-602. PubMed ID: 72605
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
    Diamantopoulos P; Zervakis K; Papadopoulou V; Iliakis T; Kalala F; Giannakopoulou N; Rougala N; Galanopoulos A; Bakarakos P; Variami E; Dimitrakopoulou A; Viniou NA
    Anticancer Res; 2015 Sep; 35(9):5141-7. PubMed ID: 26254419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Custer RP
    Neoplasma; 1973; 20(3):303-9. PubMed ID: 4125219
    [No Abstract]   [Full Text] [Related]  

  • 14. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
    Villela L; Anders V; Bolaños-Meade J
    Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.
    Wermke M; Thiede C; Kiani A; Ehninger G; Bornhäuser M; Platzbecker U
    Leukemia; 2010 Jan; 24(1):236-7. PubMed ID: 19776758
    [No Abstract]   [Full Text] [Related]  

  • 16. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
    Lainey E; Wolfromm A; Marie N; Enot D; Scoazec M; Bouteloup C; Leroy C; Micol JB; De Botton S; Galluzzi L; Fenaux P; Kroemer G
    Oncogene; 2013 Sep; 32(37):4331-42. PubMed ID: 23085751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible renal dysfunction due to 5-azacytidine.
    Greenberg MS
    Cancer Treat Rep; 1979 May; 63(5):806. PubMed ID: 88261
    [No Abstract]   [Full Text] [Related]  

  • 18. Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
    Yamamoto R; Yokoyama A; Yoneda M; Ohashi K; Hosoda T; Kagoo T; Boku S; Ueno H; Yano T
    Ann Hematol; 2014 Dec; 93(12):2081-2. PubMed ID: 24863693
    [No Abstract]   [Full Text] [Related]  

  • 19. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 20. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
    Ramos F; Thépot S; Pleyer L; Maurillo L; Itzykson R; Bargay J; Stauder R; Venditti A; Seegers V; Martínez-Robles V; Burgstaller S; Récher C; Debén G; Gaidano G; Gardin C; Musto P; Greil R; Sánchez-Guijo F; Fenaux P;
    Leuk Res; 2015 Mar; 39(3):296-306. PubMed ID: 25601157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.